Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. - Wikidata - awgldk - TriplyDB

Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.

Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.

http://www.wikidata.org/entity/Q33827358

about

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.Evidence for the prevention and treatment of stroke in dialysis patients Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.Alterations in cardiac structure and function in hypertension Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to com Intersection of cardiovascular disease and kidney disease: atrial fibrillation.Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management.B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis.High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.Cardiac biomarkers and health-related quality of life in new hemodialysis patients without symptomatic cardiac disease.Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study.The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial Gender-specific association of decreased estimated glomerular filtration rate and left vertical geometry in the general population from rural Northeast China A longitudinal study of left ventricular function and structure from CKD to ESRD: the CRIC study Association of Dialysis Duration with Outcomes after Transplantation in a Japanese Cohort.Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study.Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.Sudden cardiac death in chronic kidney disease: epidemiology and prevention.Most important chronic complications of arteriovenous fistulas for hemodialysis.Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.How Dangerous Is Hyperkalemia?Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.Cardiovascular complications in chronic dialysis patients.Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study.Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.Diastolic dysfunction and high levels of new cardiac biomarkers as risk factors for cardiovascular events and mortality in hemodialysis patients.Hypertension, fluid overload and micro inflammation are associated with left ventricular hypertrophy in maintenance hemodialysis patients.BMI, spKt/V, and SBP but not DBP are related to LVH in Chinese maintenance hemodialysis patients.Renal denervation decreases susceptibility of the heart to ventricular fibrillation in a canine model of chronic kidney disease.N-Terminal pro-brain natriuretic peptide as a predictor of heart failure with preserved ejection fraction in hemodialysis patients without fluid overload.Why does the treatment of anaemia not improve cardiac outcomes in CKD?Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?The intuitive case for β-blockers in patients with ESRD.Renal dysfunction in heart failure with a preserved ejection fraction: cause or consequence?

P2860

Q24187089-DAEB4F33-13A9-4EFB-9FF0-4EB9CCB87F96 Q24187413-B53308D7-E6BC-4C06-97E8-C2ED52804DB2 Q24194545-23D2B0C6-DA8A-45EE-856E-F0FA52FF142A Q26773120-7AE993D3-97CE-4C67-9000-B99E3DBAA3F4 Q27023274-5ABBFAE2-C74C-4CC2-80DC-E1F1A63226AF Q27342649-B0BE83B7-8DCD-475A-9474-61740A1FC967 Q33732380-D91C3FF7-D83E-4F4F-BDEC-7F875854E904 Q33960590-DDCDF1C5-3AD8-49AA-B6FF-A60DA580585D Q34040279-0CAEBC30-8667-4149-B521-5930E8399692 Q34133189-B46B5C92-AA99-4979-9A34-F684BE33F5FB Q34572435-6B40EFBA-2AC0-4538-8762-518D6FE2BD35 Q35043782-B5076375-54BA-43F8-A51A-C3042E0EAC60 Q35228547-4C1149EB-F4A8-4CC9-937C-167FFA8B082E Q35674143-80B89E44-9474-4579-9408-48460FE26CBA Q35739189-337D90F5-CD51-46EB-B1B8-D3B95EB92CB1 Q36025666-ABBE2624-64CB-4E8E-BA6A-A3BFAB05F1AE Q36249262-43A9EFEA-9787-423C-BAF6-6CD62E7AEDF2 Q36652810-6C618C26-9672-4E9A-AF93-658E9FC5B1DA Q36687035-ED289972-7E1B-4D33-9490-30B7A79B2833 Q36770929-8E6D2A5D-042D-4F2B-AF75-BF245D29ED6B Q37113344-BFB4C50F-D177-41FB-87CA-056F54AC032D Q37574305-47B7BEDB-FFD0-4A33-9885-C786358ED59A Q37833896-F2FD4620-7E7F-4105-991E-EFB376484B0E Q38057947-FFD64ADC-49A3-4C6D-A46A-95A288C87856 Q38258133-7FFD5FA9-9CA5-43C9-B5E4-913451CFE420 Q38639874-3A01B00F-31C7-4A3E-862B-07EC07F4D27E Q38727741-E831782B-3AC1-4AAD-AE8A-8A59DFEB1998 Q38837657-24857C6D-5642-448F-B23C-E0ACAEB375D0 Q38956399-7A755EC6-47EC-4324-9E1F-B6F0D15F4333 Q40721152-A79A9A7D-8B38-4DC6-9260-A9490448809D Q40882922-AEBA811D-3D0F-43CC-B2BE-04C03B2F9A62 Q43956069-2384797F-3ECA-4C40-8E72-8033F1A1C8AD Q44459137-706F2F3B-5FFB-4075-BCA7-BFB41E1EB95F Q45915059-63287D6B-7531-4D3B-B6D2-38B635243EC4 Q47915999-BE44BC0F-F118-4A34-96AD-165CB8D32B9C Q48798746-C5D1F9DE-65B2-437F-A898-33749AE07152 Q49064969-1574DA56-E2FD-4F02-AC1A-3726AE94475E Q51139092-DA6D2B33-270C-4571-B006-B939A2133B95 Q51636115-7CEADC46-4CDE-49BC-8594-2238E27C41B6 Q54320351-01337E62-8EB6-4357-87ED-5221963A9AC1

P2860

Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.

http://www.wikidata.org/entity/Q33827358

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@ast

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@en

type

label

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@ast

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@en

prefLabel

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@ast

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@en

P1433

Q33827358-A0EC580A-25AF-4EDD-9C47-9479CC37D197

P1476

Q33827358-F444EAF8-09A8-47B7-A39C-9B139D17326A

P2093

Q33827358-016DE268-8BD5-4B97-BEEF-DCAAE7C0EE11

Q33827358-171875B3-10AE-4D9F-8E31-EA82CE1CB4D2

Q33827358-2CE8471C-CE13-4E14-8F65-BCD1C32D3428

Q33827358-A9C4477B-045E-48AA-908F-1F7C94F75441

P2860

Q33827358-001CA06D-EE14-46FF-9E46-FC48FD47FD96

Q33827358-0281004D-4803-4C51-ADCD-5CCF35DEC138

Q33827358-1252AD6C-2279-4541-810A-0E253FFD1739

Q33827358-2732E0C0-F797-404F-85C5-8027A60BFCD4

Q33827358-2DB0A030-793A-42DE-9787-F47924613F62

Q33827358-2DF272B5-93DB-4BD8-8109-1EEA4A34DC31

Q33827358-72406778-C374-42E4-A15E-D7BFC8C10B7E

Q33827358-79539862-560F-42DC-B785-7AB46E3DD969

Q33827358-A81BC6EE-7962-4512-93AA-6E5D055DDB16

Q33827358-C3FCEC3C-67EA-4AFC-8313-4EE6B32D8B6A

P304

Q33827358-0030B365-74AA-40BE-AE22-22ED6A813DE3

P31

Q33827358-2F7E17C7-DF28-40F7-B5A8-179AFD58DD81

P356

Q33827358-5C954C07-F6C8-41C6-98F1-CE48360E21D8

P433

Q33827358-A0BC722D-4735-45CC-B1E4-301AB9149D34

P478

Q33827358-5F963B57-1978-411D-80D3-16C3848DF2C9

P577

Q33827358-91921833-6343-4CC0-9390-B5E382858DF7

P5875

Q33827358-D114C7BC-FD64-4D4C-AB91-1B5260DF932A

P698

Q33827358-A2B385E5-BB24-469E-B355-5C87776F28D1

P932

Q33827358-48F86BDE-19F9-4234-BED6-B61D69000785

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Left ventricular hypertrophy i ...... t symptomatic cardiac disease.

@en

P2093

Bryan M Curtis

http://www.w3.org/2001/XMLSchema#string

Edward W Randell

http://www.w3.org/2001/XMLSchema#string

Patrick S Parfrey

http://www.w3.org/2001/XMLSchema#string

Robert N Foley

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis

Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods.

Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements

Long-term evolution of cardiomyopathy in dialysis patients.

Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure.

Changing relationship of blood pressure with mortality over time among hemodialysis patients.

Left ventricular hypertrophy in renal disease: beyond preload and afterload.

Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease.

LV mass index significantly impacts on patient and renal outcomes in patients with coronary artery bypass grafting and poor left-ventricular function.

Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.

P304

805-813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.07761109

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43079973

http://www.w3.org/2001/XMLSchema#string

P698

20378644

http://www.w3.org/2001/XMLSchema#string

P932

2863966

http://www.w3.org/2001/XMLSchema#string